Results 81 to 90 of about 149,259 (318)

Severe autosomal dominant polycystic kidney disease [PDF]

BMJ Case Reports, 2018
A 61-year-old man with a known history of autosomal dominant polycystic kidney disease (ADPKD) and stage IV chronic kidney disease presented with a 6-month history of abdominal pain, nausea, vomiting and fatigue. In addition to the ADPKD, the right kidney had a 4.4 cm inferior pole mass concerning for renal cell carcinoma (RCC).
Neal S Gerstein, Craig E Rumbaugh, Julie M Riley   +2 more
openaire   +2 more sources

Gynecological surgery in patients with kidney failure on chronic kidney replacement therapy: A binational data linkage study of morbidity and mortality outcomes

International Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective This study evaluates postoperative outcomes of patients with kidney failure on chronic kidney replacement therapy after gynecological surgery. Methods This binational data‐linkage study identified patients with kidney failure via the Australia and New Zealand Dialysis and Transplant Registry who underwent major gynecological ...
Mina Khair, Dharmenaan Palamuthusingam, Carmel M. Hawley, Elaine M. Pascoe, Usama Shahid, David W. Johnson, Magid Fahim   +6 more
wiley   +1 more source

Fetal polycystic kidney disease: Pathological overview

Journal of the Scientific Society, 2013
Polycystic kidney disease is a rare developmental anomaly inherited as autosomal dominant or autosomal recessive. It is characterized by cystic dilatation of the collecting ducts frequently associated with hepatic involvement and progression to renal ...
Sunita B Patil, Madhura D Paricharak, Deepak G Paricharak, S S More   +3 more
doaj   +1 more source

Autosomal Dominant Polycystic Kidney Disease: Core Curriculum 2016.

American Journal of Kidney Diseases, 2016
Autosomal dominant polycystic kidney disease (ADPKD) is the most common monogenic kidney disease. It is characterized by relentless development of kidney cysts, hypertension, and eventually end-stage renal disease (ESRD).
F. Chebib, V. Torres
semanticscholar   +1 more source

Emerging targeted strategies for the treatment of autosomal dominant polycystic kidney disease. [PDF]

, 2018
Autosomal dominant polycystic kidney disease (ADPKD) is a widespread genetic disease that leads to renal failure in the majority of patients. The very first pharmacological treatment, tolvaptan, received Food and Drug Administration approval in 2018 ...
Bourgeois, Bryan C, Kruger, Samantha L, Shillingford, Jonathan M, Torres, Jacob, Weimbs, Thomas   +4 more
core   +1 more source

Inference and Prediction Using Functional Principal Components Analysis: Application to Diabetic Kidney Disease Progression in the Chronic Renal Insufficiency Cohort (CRIC) Study [PDF]

arXiv, 2022
Repeated longitudinal measurements are commonly used to model long-term disease progression, and timing and number of assessments per patient may vary, leading to irregularly spaced and sparse data. Longitudinal trajectories may exhibit curvilinear patterns, in which mixed linear regression methods may fail to capture true trends in the data.
arxiv  

Hypertension in Autosomal Dominant Polycystic Kidney Disease [PDF]

Advances in Chronic Kidney Disease, 2010
Hypertension is common and occurs in a majority of autosomal dominant polycystic kidney disease (ADPKD) patients before the loss of kidney function. Hypertension relates to progressive kidney enlargement and is a significant independent risk factor for progression to ESRD.
Konrad Stepniakowski, Frederic F. Rahbari-Oskoui, Arlene B. Chapman   +2 more
openaire   +3 more sources

Human asthenozoospermia: Update on genetic causes, patient management, and clinical strategies

Andrology, EarlyView.
Abstract Background In mammals, sperm fertilization potential relies on efficient progression within the female genital tract to reach and fertilize the oocyte. This fundamental property is supported by the flagellum, an evolutionarily conserved organelle, which contains dynein motor proteins that provide the mechanical force for sperm propulsion and ...
Emma Cavarocchi, Maëva Drouault, Joao C. Ribeiro, Violaine Simon, Marjorie Whitfield, Aminata Touré   +5 more
wiley   +1 more source

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease [PDF]

, 2010
BACKGROUND: In autosomal dominant polycystic kidney disease (ADPKD), aberrant activation of the mammalian target of rapamycin (mTOR) pathway is associated with progressive kidney enlargement. The drug sirolimus suppresses mTOR signaling. METHODS: In this
Kistler, A D, Krauer, F, Kristanto, P, Poster, D, Raina, S, Rentsch, K M, Scheffel, H, Senn, O, Serra, A L, Spanaus, K S, Weishaupt, D, Wüthrich, R P, Young, J   +12 more
core   +1 more source

Polycystic Kidney Disease Drug Development: A Conference Report

Kidney Medicine, 2023
Autosomal dominant polycystic kidney disease (ADPKD) is part of a spectrum of inherited diseases that also includes autosomal recessive polycystic kidney disease, autosomal dominant polycystic liver disease, and an expanding group of recessively ...
Max C. Liebau, Djalila Mekahli, Ronald Perrone, Belle Soyfer, Sorin Fedeles   +4 more
doaj